J Natl Cancer Inst:高维生素B6和叶酸循环浓度能否降低肺癌风险?

2017-11-01 佚名 环球医学

发表在《J Natl Cancer Inst》上的一项巢氏病例对照研究,调查了循环叶酸、维生素B6和蛋氨酸与肺癌风险的关系。研究结果显示:在避免低叶酸和维生素B6循环浓度的曾吸烟者中观察到小幅度的肺癌风险降低。

发表在《J Natl Cancer Inst》上的一项巢氏病例对照研究,调查了循环叶酸、维生素B6和蛋氨酸与肺癌风险的关系。研究结果显示:在避免低叶酸和维生素B6循环浓度的曾吸烟者中观察到小幅度的肺癌风险降低。

背景:在欧洲癌症和营养(EPIC)的前瞻性调查研究中,维生素B的循环浓度和一碳单位代谢相关因素与肺癌风险强烈负相关。这种关联在其他研究人群中的程度仍不清楚。

方法:在来自国家癌症研究所队列联盟的20项前瞻性队列中,一项巢氏病例对照研究被设计,包括5364名突发性肺癌病例患者和5364名对照受试者,根据年龄、性别、队列和吸烟状态匹配至病例患者。集中的生化分析被开展,用于检测维生素B6、叶酸和蛋氨酸的循环浓度,并且将可替宁作为近期烟草暴露的因素。采用条件逻辑回归模型评估生物标志物和肺癌风险之间的相关性。

结果:高维生素B6和叶酸循环浓度能适度降低受试者肺癌风险,高4分位浓度和低4分位浓度肺癌风险比较时的比值比(OR4vs1)分别是0.88(95%置信区间[CI]=0.78至1.00)和0.86(95%CI=0.74至0.99)。研究人员发现在男性当中(维生素B6:OR4vs1=0.74,95%%CI=0.62至0.89;叶酸:OR4vs1=0.75,95%=0.61至0.93)和曾经吸烟者当中(维生素B6:OR4vs1=0.78,95%%CI=0.67至0.91;叶酸:OR4vs1=0.87,95%=0.73至1.03)的相关性更显着。研究人员进一步发现叶酸的相关性局限于欧洲/澳洲和亚洲,而在美国未观察到显着的相关性。蛋氨酸的循环浓度与总的或重要亚组的肺癌风险无关。

结论:尽管无法排除烟草暴露或反向因果关系导致的混淆作用,但这些研究结果是一致的,即在避免低叶酸和维生素B6循环浓度的曾吸烟者中观察到小幅度的肺癌风险降低。

原始出处:

Anouar Fanidi,et ai.,Circulating Folate, Vitamin B6, and Methionine in Relation to Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3).J Natl Cancer Inst.Volume 110, Issue 1, 1 January 2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2045557, encodeId=0323204555e50, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Nov 15 11:12:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061684, encodeId=d33720616846f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 01 21:12:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882590, encodeId=f9121882590c9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 14 22:12:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977536, encodeId=1ff719e753665, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Feb 23 14:12:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950217, encodeId=95ce195021e39, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jan 11 01:12:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484197, encodeId=8b66148419e00, content=<a href='/topic/show?id=bce6e90631c' target=_blank style='color:#2F92EE;'>#维生素B6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79063, encryptionId=bce6e90631c, topicName=维生素B6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74fe7959907, createdName=ms1692810954239974, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508528, encodeId=e1481508528cc, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544480, encodeId=08f11544480fa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2045557, encodeId=0323204555e50, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Nov 15 11:12:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061684, encodeId=d33720616846f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 01 21:12:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882590, encodeId=f9121882590c9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 14 22:12:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977536, encodeId=1ff719e753665, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Feb 23 14:12:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950217, encodeId=95ce195021e39, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jan 11 01:12:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484197, encodeId=8b66148419e00, content=<a href='/topic/show?id=bce6e90631c' target=_blank style='color:#2F92EE;'>#维生素B6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79063, encryptionId=bce6e90631c, topicName=维生素B6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74fe7959907, createdName=ms1692810954239974, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508528, encodeId=e1481508528cc, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544480, encodeId=08f11544480fa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2018-05-01 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=2045557, encodeId=0323204555e50, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Nov 15 11:12:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061684, encodeId=d33720616846f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 01 21:12:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882590, encodeId=f9121882590c9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 14 22:12:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977536, encodeId=1ff719e753665, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Feb 23 14:12:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950217, encodeId=95ce195021e39, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jan 11 01:12:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484197, encodeId=8b66148419e00, content=<a href='/topic/show?id=bce6e90631c' target=_blank style='color:#2F92EE;'>#维生素B6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79063, encryptionId=bce6e90631c, topicName=维生素B6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74fe7959907, createdName=ms1692810954239974, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508528, encodeId=e1481508528cc, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544480, encodeId=08f11544480fa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2018-03-14 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2045557, encodeId=0323204555e50, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Nov 15 11:12:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061684, encodeId=d33720616846f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 01 21:12:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882590, encodeId=f9121882590c9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 14 22:12:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977536, encodeId=1ff719e753665, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Feb 23 14:12:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950217, encodeId=95ce195021e39, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jan 11 01:12:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484197, encodeId=8b66148419e00, content=<a href='/topic/show?id=bce6e90631c' target=_blank style='color:#2F92EE;'>#维生素B6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79063, encryptionId=bce6e90631c, topicName=维生素B6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74fe7959907, createdName=ms1692810954239974, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508528, encodeId=e1481508528cc, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544480, encodeId=08f11544480fa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2018-02-23 drj2003
  5. [GetPortalCommentsPageByObjectIdResponse(id=2045557, encodeId=0323204555e50, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Nov 15 11:12:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061684, encodeId=d33720616846f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 01 21:12:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882590, encodeId=f9121882590c9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 14 22:12:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977536, encodeId=1ff719e753665, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Feb 23 14:12:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950217, encodeId=95ce195021e39, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jan 11 01:12:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484197, encodeId=8b66148419e00, content=<a href='/topic/show?id=bce6e90631c' target=_blank style='color:#2F92EE;'>#维生素B6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79063, encryptionId=bce6e90631c, topicName=维生素B6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74fe7959907, createdName=ms1692810954239974, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508528, encodeId=e1481508528cc, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544480, encodeId=08f11544480fa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2018-01-11 qidongfanjian
  6. [GetPortalCommentsPageByObjectIdResponse(id=2045557, encodeId=0323204555e50, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Nov 15 11:12:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061684, encodeId=d33720616846f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 01 21:12:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882590, encodeId=f9121882590c9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 14 22:12:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977536, encodeId=1ff719e753665, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Feb 23 14:12:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950217, encodeId=95ce195021e39, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jan 11 01:12:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484197, encodeId=8b66148419e00, content=<a href='/topic/show?id=bce6e90631c' target=_blank style='color:#2F92EE;'>#维生素B6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79063, encryptionId=bce6e90631c, topicName=维生素B6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74fe7959907, createdName=ms1692810954239974, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508528, encodeId=e1481508528cc, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544480, encodeId=08f11544480fa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2045557, encodeId=0323204555e50, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Nov 15 11:12:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061684, encodeId=d33720616846f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 01 21:12:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882590, encodeId=f9121882590c9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 14 22:12:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977536, encodeId=1ff719e753665, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Feb 23 14:12:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950217, encodeId=95ce195021e39, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jan 11 01:12:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484197, encodeId=8b66148419e00, content=<a href='/topic/show?id=bce6e90631c' target=_blank style='color:#2F92EE;'>#维生素B6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79063, encryptionId=bce6e90631c, topicName=维生素B6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74fe7959907, createdName=ms1692810954239974, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508528, encodeId=e1481508528cc, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544480, encodeId=08f11544480fa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2017-11-03 马龙
  8. [GetPortalCommentsPageByObjectIdResponse(id=2045557, encodeId=0323204555e50, content=<a href='/topic/show?id=f6cf8225325' target=_blank style='color:#2F92EE;'>#肺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82253, encryptionId=f6cf8225325, topicName=肺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Nov 15 11:12:00 CST 2017, time=2017-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061684, encodeId=d33720616846f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue May 01 21:12:00 CST 2018, time=2018-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882590, encodeId=f9121882590c9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 14 22:12:00 CST 2018, time=2018-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977536, encodeId=1ff719e753665, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Feb 23 14:12:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1950217, encodeId=95ce195021e39, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Jan 11 01:12:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484197, encodeId=8b66148419e00, content=<a href='/topic/show?id=bce6e90631c' target=_blank style='color:#2F92EE;'>#维生素B6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79063, encryptionId=bce6e90631c, topicName=维生素B6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74fe7959907, createdName=ms1692810954239974, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508528, encodeId=e1481508528cc, content=<a href='/topic/show?id=68b0e9055f7' target=_blank style='color:#2F92EE;'>#维生素B#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79055, encryptionId=68b0e9055f7, topicName=维生素B)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17599981768, createdName=马龙, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544480, encodeId=08f11544480fa, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Fri Nov 03 05:12:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]

相关资讯

Thorax:肺癌、遗传易感性和吸烟:双胞胎研究

遗传性的作用随着年龄的增长而降低。吸烟情况不一致的双胞胎分析证实了吸烟会导致肺癌。

治疗肺癌,到底什么样的免疫疗法有效?

现在要谈癌症治疗,必然离不开的话题就是免疫疗法。

SCI REP:肺癌的发病率和死亡率:全球趋势和与社会经济状况的关联

国家特异性HDI与年龄标准化发病率和死亡率呈强相关性。

PLoS One:前列腺特异性膜抗原(PSMA)在非小细胞肺癌中的表达

在使用放射性标记的PSMA配体进行潜在治疗的背景下,这项研究的数据未来可用于识别能够从这种治疗中受益的患者。

J Natl Cancer Inst:中科院周光飚研究组发现肺癌精准治疗新标记

发现基因及其编码蛋白质的异常是癌症精准治疗的基础。局部黏着斑激酶(focal adhesion kinase, FAK)是一种重要的非受体型酪氨酸激酶,在几乎所有的细胞中均有表达,可将细胞外的重要信号(如细胞生长、营养等)向细胞内传导,调控细胞的基本生物学功能。FAK在肺癌等肿瘤中表达增高并与病人预后负相关,抑制FAK在临床试验中显示一定的抗癌活性。然而,目前缺乏指导FAK抑制剂临床应用的生物标记

[WCLC2017]大咖圆桌会:多学科专家共话肺癌EGFR TKI靶向治疗热点

第18届世界肺癌大会(WCLC)于10月15~18日在日本横滨召开。会议期间,我们特别邀请到上海市肺科医院周彩存教授、首都医科大学宣武医院支修益教授、北京大学肿瘤医院林冬梅教授和浙江省肿瘤医院范云教授接受采访。四位专家的专业领域涵盖了内、外科和分子病理,从多个视角分享了本次参加WCLC的感受,并对大家关心的肺癌EGFR TKI治疗问题进行了深入的探讨。